Study suggests new anti-KRAS drug as a strong candidate for pancreatic cancer clinical trials

Digital transformation conceptual for next generation technology era

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine’s Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials.

When does mental distress become a mental illness?

Previous article

Following insect ‘footprints’ to improve crop resilience and monitor pollinator biodiversity

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News